deTACE间隔时间86天.pdf

CLINICAL STUDY Transcatheter Arterial Chemoembolization with Doxorubicin-Eluting Superabsorbent Polymer Microspheres in the Treatment of Hepatocellular Carcinoma: Midterm Follow-up Jeroen Dekervel, MD, Hannah van Malenstein, MD, PhD, Vincent Vandecaveye, MD, PhD, Frederik Nevens, MD, PhD, Jos van Pelt, Dr, Ing, Sam Heye, MD, PhD, Wim Laleman, MD, PhD, Werner Van Steenbergen, MD, PhD, Johan Vaninbroukx, MD, Chris Verslype, MD, PhD, and Geert Maleux, MD, PhD ABSTRACT Purpose: To investigate prospectively the safety, tolerability, and efficacy of transarterial chemoembolization using super- absorbent polymer (SAP) microspheres loaded with doxorubicin for the treatment of hepatocellular carcinoma (HCC). Materials and Methods: During the years 2006–2011, 64 patients underwent 144 transarterial chemoembolization with SAP microspheres procedures. Most of the patients were staged as Barcelona Clinic Liver Cancer class B (65%). The most frequent underlying liver diseases were hepatitis C (35%) and alcoholic liver disease (28%) resulting in Child-Pugh A (73.4%) or Child- Pugh B (17%) liver cirrhosis. Tumor response was assessed using modified Response Evaluation Criteria in Solid Tumors with magnetic resonance (MR) imaging performed 4–6 weeks after each procedure. Results: Serious adverse events (n ¼ 9) were ischemic or infectious in nature. Transarterial chemoembolization with SAP microspheres resulted in objective response rates of 67.5%, 44.5%, and 25% after first, second, and third sessions. There were 16 patients (25%) who underwent orthotopic liv